MDxHealth SA

MDxHealth reported Q1 2026 results, with revenue up 13% to $27.4 million and a net loss of $8.9 million. The company announced a strategic decision to discontinue its Resolve UTI offering and laboratory operations in Plano, Texas, citing an increasingly uncertain reimbursement landscape and a recent Medicare policy reversal. This proactive exit allows MDxHealth to focus on its core prostate cancer precision diagnostics business, for which it set updated 2026 revenue guidance of $110-115 million, representing 20-26% year-over-year growth. The company also initiated an AI-dedicated strategic initiative to enhance operations and clinical value, despite facing a $10.4 million Medicare recoupment decision for Resolve mdx claims.

MDxHealth reported its Q1 2026 financial results, with revenue increasing 13% to $27.4 million and net loss decreasing 4% to $(8.9) million. The company announced a strategic decision to discontinue its Resolve UTI offering and Plano, Texas laboratory operations due to an uncertain reimbursement landscape, aiming to refocus on its core prostate cancer precision diagnostics business. MDxHealth also updated its 2026 revenue guidance for the core cancer business to $110-115 million, representing 20-26% year-over-year growth, and disclosed a contested $10.4 million Medicare recoupment decision related to Resolve mdx claims.

MDxHealth SA announced it will release its financial results for the first quarter ended March 31, 2026, after market close on Wednesday, May 13, 2026. The company will host a conference call and webcast with live Q&A on the same day at 4:30pm ET / 22:30 CET to discuss the results and provide a corporate update. Dial-in details and a webcast link are provided for interested participants, with a replay available on the company's website.

MDxHealth SA announced its Ordinary and Extraordinary General Shareholders Meetings to be held on Thursday, May 28, 2026, at 3:00 p.m. Belgian time. The meetings will take place at the offices of a notary public in Ghent, Belgium. The agenda for these meetings includes proposals related to a 2026 Share Option Plan, the 2026 Exact Sciences Warrant Terms and Conditions, and the renewal of the authorized capital.